The length of time that you use Semaglutide is dependent on your desired results
Anti-Doping Agency (USADA). It falls under Category S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics on the WADA Prohibited List, often specified as a "Growth Hormone Releasing Hormone (GHRH) and its analogues" or a "Growth Hormone Secretagogue (GHS)". The ban is due to its potential to unfairly enhance athletic performance by increasing muscle mass, strength, reducing fat, and improving recovery. The prohibition applies regardless of its mechanism of stimulating endogenous GH, as the outcome of artificially elevated GH/IGF-1 is the concern

The standard dosing schedule starts at 2.5 mg weekly and escalates every four weeks: Weeks 14: 2.5 mg weekly (initiation dose to acclimate to GLP-1/GIP receptor activation) Weeks 58: 5 mg weekly Weeks 912: 7.5 mg weekly (optional intermediate step) Weeks 1316: 10 mg weekly Weeks 1720: 12.5 mg weekly (optional intermediate step) Week 21 onward: 15 mg weekly (maximum maintenance dose) Tirzepatide is injected subcutaneously just under the skin using a pre-filled pen or syringe
investigators design protocols based on their specific research question and institutional guidelines
Pumpkin seed oil, biotin and hair loss pills Mostly no